Myasthenia Gravis - Pipeline Review, H2 2019

Published: November 2019

No. of Pages: 181

Price:

Single User License: US $ 2000

Corporate User License: US $ 6000

Report Description
Table of Contents

Avail Buy One-Get One Report Free on All GlobalMarketsDirect publisher Reports till 13 December 2019. To avail discount please contact at +1-888-391-5441 / [email protected]

Myasthenia Gravis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 5, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Avail Buy One-Get One Report Free on All GlobalMarketsDirect publisher Reports till 13 December 2019. To avail discount please contact at +1-888-391-5441 / [email protected]

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis - Overview
Myasthenia Gravis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myasthenia Gravis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myasthenia Gravis - Companies Involved in Therapeutics Development
Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Argenx SE
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
Cabaletta Bio Inc
CuraVac Inc
Grifols SA
HanAll Biopharma Co Ltd
Kashiv BioSciences LLC
Momenta Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc
Myasthenia Gravis - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amifampridine phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1616 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVMG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Descartes-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iscalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPL-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPL-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nipocalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPO-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orilanolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06755347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-3034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Featured News & Press Releases
Oct 07, 2019: Cabaletta Bio announces presentation of preclinical data showing specific CAAR T activity against Anti-MuSK expressing B Cells
Oct 02, 2019: Ra Pharmaceuticals announces dosing of first patient in global phase 3 pivotal study of Zilucoplan for gMG
Sep 04, 2019: Ra Pharmaceuticals receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Myasthenia Gravis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myasthenia Gravis - Pipeline by Ahead Therapeutics SL, H2 2019
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2019
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2019
Myasthenia Gravis - Pipeline by Argenx SE, H2 2019
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2019
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Myasthenia Gravis - Pipeline by Cabaletta Bio Inc, H2 2019
Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2019
Myasthenia Gravis - Pipeline by Grifols SA, H2 2019
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Myasthenia Gravis - Pipeline by Kashiv BioSciences LLC, H2 2019
Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2019
Myasthenia Gravis - Pipeline by Novartis AG, H2 2019
Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2019
Myasthenia Gravis - Pipeline by Protalex Inc, H2 2019
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2019
Myasthenia Gravis - Pipeline by Tolerion Inc, H2 2019
Myasthenia Gravis - Pipeline by UCB SA, H2 2019
Myasthenia Gravis - Pipeline by Viela Bio Inc, H2 2019
Myasthenia Gravis - Dormant Projects, H2 2019
Myasthenia Gravis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Myasthenia Gravis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Published By: Global Markets Direct

Product Code: Global Markets Direct2374

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Dalbavancin Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The worldwide market for Dalbavancin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report f...
Global Ceftaroline Fosamil Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The worldwide market for Ceftaroline Fosamil is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This ...
Global Epidural Anesthetic Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The worldwide market for Epidural Anesthetic Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. ...
Global Pumpkin Seed Oil Supplements Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The worldwide market for Pumpkin Seed Oil Supplements is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study....
Global Iron Deficiency Anemia Drug Market 2019 by Company, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The global Iron Deficiency Anemia Drug market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market sha...
Global Sialic Acid Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The worldwide market for Sialic Acid is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report f...
Global OAB Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024 Description Scope of the Report: The global OAB Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in followin...
Global CD19 (Antibody) Market Professional Survey Report 2019 The global CD19(Antibody) market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on CD19(Antibody) volume and value at global level, regional level and company level. From a global perspective,...
Global Emergency Medicine Market Professional Survey Report 2019 The global Emergency Medicine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Emergency Medicine volume and value at global level, regional level and company level. From a global pers...
Global Antibacterial Drug Resistance Market Professional Survey Report 2019 The global Antibacterial Drug Resistance market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Antibacterial Drug Resistance volume and value at global level, regional level and company lev...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *